ReviewCureus2025
The Practical Management of Intractable Haematuria Within the National Health Service of the United Kingdom: A Literature Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to provide an updated review of the practical management of intractable haematuria in the National Health Service (NHS) of the United Kingdom (UK). A literature search was performed using the PubMed Advanced Search Builder. The terms 'Intractable Haematuria' OR 'Haemorrhagic Cystitis' OR 'Radiation Cystitis' were entered in a joint search as terms in a given publication's title only. This generated 295 papers in total, which were manually screened for suitability. There were no specific inclusion or exclusion criteria. We liaised with senior pharmacists in our Medicine Information department to assess product availability. Based on the best available evidence, we propose a new treatment escalation plan for the management of intractable haematuria based on the safety profile and product availability in the UK. After initial management, first-line treatment could include intravesical hyaluronic acid, tranexamic acid, carboprost, adrenaline, or PuraStat®. Second-line treatment could include hyperbaric oxygen therapy or super selective embolisation. Percutaneous diversion and cystectomy represent last resorts. Not all proposed options for the management of intractable haematuria published in the literature are of practical use in the UK, and each has its own merits and disadvantages. The evidence base for the majority of treatment modalities recommended in the literature is overall weak, with a lack of appropriate randomised controlled trials to support their use. More research is required on available treatments and potentially novel treatments in order to drive a robust national census to serve the often morbid patient cohort presenting with intractable haematuria in the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.